Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients

Roig et al., Revista Espanola de Quimioterapia, doi:10.37201/req/130.2020

Jan 2021

Source PDF All Studies Meta AnalysisMeta

Retrospective 79 hospitalized nonagenarian patients showing unadjusted HCQ mortality RR 0.84, p = 0.76.

Although the 16% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 247 mortality results to date.

This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

Important missing comments or errors? Let us know.

risk of death, 15.6% lower, RR 0.84, p = 0.76, treatment 33 of 67 (49.3%), control 7 of 12 (58.3%), NNT 11.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Roig et al., 31 Jan 2021, retrospective, Spain, peer-reviewed, 6 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients

Sara Ortonobes Roig, Nuria Soler-Blanco, Isabel Torrente Jiménez, Eva Van Den Eynde Otero, Marc Moreno-Ariño, Mònica Gómez-Valent

Revista Española de Quimioterapia, doi:10.37201/req/130.2020

Introduction. Despite the impact of SARS-CoV-2 infection in geriatrics, data on nonagenarian patients is scarce. The aim of this study is to describe the clinical features of COVID-19-diagnosed nonagenarians, as well as its clinical evolution and therapeutic response. Material and methods. Retrospective observational study of nonagenarians, admitted for COVID-19. Sociodemographic and clinical variables were registered, including previous polypharmacy. Blood analysis data and COVID-19-specific treatment were registered. Results. A total of 79 patients were included, with 50.6% (40 patients) of mortality. None of the comorbidities registered correlated with mortality, which was significantly higher among patients with moderate/complete functional dependence, compared to those mild-dependents/independents (59.5% vs 40.5%; p=0.015). Most prescribed drugs were hydroxychloroquine/chloroquine and azithromycin. Non-survivors presented higher counts of leukocytes and neutrophils, and higher lymphopenia. Conclusions. Nonagenarians with functional dependence presented higher mortality, irrespective of comorbidities or treatment received. Implementing an integral geriatric evaluation would enhance the implementation of personalized therapeutic strategies for nonagenarians.

References

Aw, Woodrow, Ogliari, Harwood, Association of frailty with mortality in older inpatients with Covid-19: a cohort study, Age Ageing, doi:10.1093/ageing/afaa184

Berenguer, Ryan, Rodríguez-Baño, Jarrín, Carratalà et al., Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.07.024

Casas-Rojo, Santos, Millán-Núñez-Cortés, Lumbreras-Bermejo, Ramos-Rincón Jm et al., Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 registry, Rev Clin Esp, doi:10.1016/j.rce.2020.07.003

Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7

Cockcroft-Gault, None, ml/min

Godaert, Proye, Demoustier-Tampere, Coulibaly, Hequet et al., Clinical characteristics of older patients: the experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France, J Infect, doi:10.1016/j.jinf.2020.04.009

Gómez-Belda, Fernández-Garcés, Sanchis, Madrazo, Carmona et al., COVID-19 in older adults: What are the differences with younger patients?, Geriatr Gerontol Int, doi:10.1111/ggi.14102

Huang, Hong, Shen, Huang, Zhao, China's oldest coronavirus survivors, J Am Geriatr Soc, doi:10.1111/jgs.16462

Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5

Lian, Hao, Cai, Zhang, Zheng, Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan, Clin Infect Dis, doi:10.1093/cid/ciaa242

Lithander, Neumann, Tenison, Lloyd, Welsh et al., COVID-19 in older people: a rapid clinical review, Age Ageing, doi:10.1093/ageing/afaa093

Liu, Chen, Lin, Han, Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients, J Infect, doi:10.1016/j.jinf.2020.03.005

Niu, Tian, Lou, Kang, Zhang et al., Clinical characteristics of older patients infected with COVID-19: a descriptive study, Arch Gerontol Geriatr, doi:10.1016/j.archger.2020.104058

Proteína, Reactiva, None

Rodríguez, Muñoz, Muela, García-Prendes, Rivera et al., Variables asociadas con mortalidad en una población de pacientes mayores de 80 años y con algún grado de dependencia funcional, hospitalizados por COVID-19 en un servicio de geriatría, Rev Esp Geriatr Gerontol, doi:10.1016/j.regg.2020.07.002

Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus diseases 2019, JAMA, doi:10.1001/jama.2020.6019

Sérica, None, ng/mL)

Yan, Zhang, Gonçalves, Xiao, Wang et al., A machine learning-based model for survival prediction in patients with severe COVID-19 infection, Medrxiv, doi:10.1101/2020.02.27.20028027

Zhang, Yu, Pan, Jiang, ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis, Pharmacol Res, doi:10.1016/j.phrs.2020.104927

Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Eng J Med, doi:10.1056/NEJMoa2001017

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0